Rhythm Pharmaceuticals (NASDAQ: RYTM) has recently received a number of price target changes and ratings updates:
- 8/7/2026 – Rhythm Pharmaceuticals had its price target raised by JPMorgan Chase & Co. from $145.00 to $146.00. They now have an “overweight” rating on the stock.
- 8/5/2026 – Rhythm Pharmaceuticals was given a new $154.00 price target by Canaccord Genuity Group Inc..
- 8/5/2026 – Rhythm Pharmaceuticals had its “market outperform” rating reaffirmed by Citigroup Inc..
- 8/5/2026 – Rhythm Pharmaceuticals was given a new $160.00 price target by National Bank Financial.
- 8/5/2026 – Rhythm Pharmaceuticals had its price target raised by Citigroup Inc. from $142.00 to $143.00. They now have a “buy” rating on the stock.
- 8/5/2026 – Rhythm Pharmaceuticals had its price target raised by Royal Bank Of Canada from $141.00 to $155.00. They now have an “outperform” rating on the stock.
- 8/5/2026 – Rhythm Pharmaceuticals had its price target raised by Citizens Jmp from $155.00 to $160.00. They now have a “market outperform” rating on the stock.
- 7/27/2026 – Rhythm Pharmaceuticals is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $145.00 price target on the stock.
- 7/17/2026 – Rhythm Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 7/7/2026 – Rhythm Pharmaceuticals had its price target raised by Royal Bank Of Canada from $137.00 to $141.00. They now have an “outperform” rating on the stock.
Insider Transactions at Rhythm Pharmaceuticals
In related news, EVP Yann Mazabraud sold 57,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $116.15, for a total transaction of $6,620,550.00. Following the completion of the transaction, the executive vice president directly owned 55,655 shares in the company, valued at $6,464,328.25. This represents a 50.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Alastair Garfield sold 7,763 shares of the stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $117.57, for a total transaction of $912,695.91. Following the completion of the transaction, the insider directly owned 2,295 shares of the company’s stock, valued at approximately $269,823.15. The trade was a 77.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 182,676 shares of company stock valued at $20,754,691. 5.90% of the stock is owned by company insiders.
The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.
See Also
- Five stocks we like better than Rhythm Pharmaceuticals
- Viking Stock Fell After Earnings, But the Numbers Tell a Different Story
- 3 Ways to Invest in Cybersecurity Through ETFs
- TJX Companies Stock Drop Sets Up Buy Signal as Analysts Stay Bullish
- Nasdaq’s 23-Hour Trading Push Could Turn Global Liquidity Into a Growth Engine
Receive News & Ratings for Rhythm Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
